Press release out today: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
30% weight loss on highest dose.
Obvs that's me adding a rough line onto a graph. Graph was originally from here: https://doi.org/10.1007/s12170-025-00770-z
(Didn't realise it was at 104 weeks so the graph is wrong, but still 30% at any time is impressive).
Apparently something happening with wegovy prices next week or the week after. Apparently some pharmacies are getting deals but they're going to change it to just one price. MMP are selling 2.4 wegovy for £135 atm but the list price for 2.4 is £174 so there's obviously a deal, and it's not just MMP. I remember a pharmacy saying during the pendemic that prices will be confirmed after the NDA has been agreed so it must have been going on since August and they've just had fantastic profit margins on wegovy.
Hopefully all pharmacies will get a fair price because atm the local community pharmacies and the pharmacies that didn't push wegovy are paying list price for wegovy. It would be nice if the savings from these deals were passed onto the patients (which I think at least most places are doing now, the price of wegovy does seem lower than a few months ago, and it's great that MMP have set the price so low.
I really don't think mounjaro prices are sustainable. November-March you could get 15mg for £220 by shopping around but recently the prices don't seem to be going down. I think the pharmacies realised the introductory deals weren't working because everyone's hopping for the best deals. And now we're hearing the new 15mg pens are coming.
CQC are in discussions with at least one clinic about click counting, I don't think CQC are keen on it.
At least next year we should have things like cagrisema on the market to compete with mounjaro.
It sucks atm though.
Managed to get the book on loan through borrowbox.
Just been skimming through it this morning.
It was written by the person that did the clinical trials. I didn't realise she was also involved in the other clinical trials too:
> Dr. Jastreboff conducts multicenter trials with Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals; serves on scientific advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Eli Lilly, IntelliHealth/Flyte, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, Scholar Rock, Structure Therapeutics, Syntis Bio, WW International, and Zealand Pharma; and is an academic cofounder of State 4 Therapeutics.
I don't think there's much in the book that we don't already know.
I think the best thing about the book is that it takes a lot of the shame out.
Dr. Jastreboff talking about her own family:
> I realized then, seeing my highly intelligent father's struggles, that a person could know what they should eat and yet be compelled by biology to do something else. At that time I did not yet understand that biology was driving his behavior, but I did know that carrying extra weight, storing extra fat, was not about choice. My father did not choose to have obesity. My mother did not choose to gain weight. My brother and I did not choose to have a genetic predisposition to weight gain, obesity, or diabetes. None of us chose to live in an environment that promotes unhealthy weight gain.
Also I like this bit near the end of the book:
> It is not about the before and after. It is about the process. It is about health mental and physical. It's about self-compassion and self-love. Alice knew and had internalized that her treatment was not about crossing an imaginary finish line. Gaining and keeping health is not about two snapshots, two moments in time. It's about a whole life, an ongoing pursuit... yes, a journey.
> When I see any before-and-after photos of patients who lost weight with these new obesity medicines, I think about all that came in between those two snapshots. I think about what the person may have felt, experienced, endured, and overcome. I also think of all that is to come-the next "after" and each of the "afters" that follow.
There's a Congress on Obesity going on at the moment. You can read all the abstracts here.
This week we've seen a few news stories come out after people have presented at the conference.
Like this story: https://www.shu.ac.uk/news/all-articles/latest-news/cew-obesity-research
And this story: https://www.reddit.com/r/mounjarouk/s/pQKqlI9hBR
I watched some coverage about the Orforglipron research and they said search the term skinny jabs to see more stories, like "what happens when you stop".
First of all the whole point of Orforglipron is to help people who want to stop mounjaro and not gain weight.
I'm going to complain about the term skinny jabs.
It's not professional journalism.
I thought they'd stopped using the term but they seem to have started again.
In the same story the BBC reported how many billions obesity is costing the NHS.
Can they not see how damaging it is to call mounjaro a skinny jab like we're all doing this for vanity? Mounjaro is saving lives and saving the NHS money.
I can understand unprofessional papers creating crazy sensationalised headlines but I'm not having the BBC do it.
This paper was embargoed until midnight. Saw the news story pop up and I couldn't sleep so thought I'd quickly read the paper in nature.
https://www.nature.com/articles/s41591-026-04386-7#MOESM3
I put the two main graphs next to each other.
People were switched from mounjaro to foundayo on the top graph and from wegovy to foundayo on the bottom graph.
Switching from wegovy to foundayo seems straight forwards, they're both GLP1s. Seems easy to maintain with foundayo after losing weight with wegovy.
With mounjaro, especially high doses, it's not quite as easy but hey I'd be happy with that, especially if foundayo is affordable. It's better than nothing. Better than previous diets where I gained 6 stone after losing 4 stone.
The paper says:
> We hypothesized that patients would experience more weight regain on average when transitioning off high doses of the dual GIP/GLP-1 RA tirzepatide to a GLP-1 RA than when transitioning from a GLP-1 RA to a GLP-1 RA, but further exploration is necessary. A head-to-head clinical trial of injectable tirzepatide versus injectable semaglutide has already demonstrated superior weight loss with tirzepatide. Even so, most participants transitioning from tirzepatide maintained the majority of their weight loss, particularly compared with placebo, and demonstrated minimal changes in waist circumference as a marker of visceral adiposity, along with sustained improvements in systolic blood pressure, lipid levels and glycemic parameters following weight reduction. For some patients, a small degree of weight regain while maintaining the majority of weight loss achieved with injectable therapy may be clinically acceptable, particularly if switching to a different therapy that has attributes that facilitate long-term persistence on therapy. The individual differences highlight the need for shared decision-making conversations across the entire obesity management journey. An additional finding is that, regardless of the initial intervention, switching to orforglipron resulted in both cohorts ending at the same body weight of 95.9 kg. This finding with orforglipron could suggest that there may be a biological component that controls the disease of obesity at this body weight. Further studies are needed to explore this potential biological control of obesity.
Looks like this paper was under an embargo until today.
Daily pill to help keep weight off after stopping obesity jabs
This is something that's quite close to my heart as someone with PCOS who's struggled with their weight since puberty.
1 in 10 women are thought to have PCOS so it could affect a lot of us.
The team are involved in public health policy. I think it's really important to get into the conversation with them so that mounjaro could be more available to people with conditions like PCOS. There's a huge health inequality due to the amount of people who are having to fund mounjaro privately and I don't think that's fair.
https://www.phc.ox.ac.uk/research/research-themes/health-behaviours
> Are you based in England with experience of using a GLP-1 agonist medication (these may include: liraglutide, semaglutide, tirzepatide, Saxenda, Wegovy, Mounjaro, or Ozempic) for weight loss? Do you have polycystic ovary syndrome?
> Living with PCOS, a common hormonal condition, can make weight management challenging. We are currently looking to interview people living with PCOS who have used these medications to learn more about their experiences and perspectives. Taking part involves a remote interview via Microsoft Teams, where we will discuss your experiences of GLP-1 use and PCOS. This is expected to take about an hour and can be scheduled at a time that suits you. You will receive a £25 shopping voucher in recognition of your time.
> If you are interested, please email me at sabrina.keating@phc.ox.ac.uk or call 01865 289295
https://ml-eu.globenewswire.com/Resource/Download/c147e6f8-b7a7-4d46-aca8-37e3d1419324
Heard this today. Now wegovy pens are fine for 48hrs in the post without ice packs etc as long as they don't go above 30°C.
Also apparently some pharmacies have been getting a special rate for wegovy as long as they sell a certain number of wegovy pens, apparently this is changing and there'll be a flat rate for all pharmacies but no idea if the wegovy prices will go up or down or stay the same. Apparently coming in 3 weeks.
Here's the info:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11650/documents
Patient Expert Expression of Interest – NICE Technology Appraisal for a new treatment for people living with a higher weight
Activity description:
NICE is evaluating whether a new medicine is suitable for use across the NHS. Orforglipron is a once‑daily tablet designed to support people living with higher weight. It works by reducing appetite and increasing feelings of fullness, helping some people eat less without feeling as hungry. It belongs to the same group of medicines as other GLP‑1 treatments (medicines that help regulate appetite, blood sugar, and digestion) but is taken as a tablet rather than an injection. This appraisal focuses on people living with higher weight who also have at least one weight‑related health condition (sometimes called a co‑morbidity), such as high blood pressure, type 2 diabetes, joint problems, or other long‑term health conditions.
We are looking for patient experts who can help the NICE committee understand the lived experience of people living with a higher weight, and what matters most to patients and carers when considering treatments like this.
You can read more about the Orforglipron for managing overweight and obesity appraisal (if you click on the ‘Project documents’ tab towards the top right hand side of the webpage, you’ll also find documents like the scope which tell you more about the plans for this guidance).
Skills & Experience Needed:
We welcome expressions of interest from people with lived experience of living with a higher weight, including where this is alongside one or more weight‑related health conditions, either as a patient or a carer. You do not need to have experience with the specific drug being appraised (Orforglipron). You will need to feel comfortable sharing your experience and views in a large meeting. Support and guidance will be provided if you are selected, including an induction before the committee meeting.
Time Commitment:
Completing a nomination form by Wednesday 22 April and, if selected, then also a personal statement (guidance provided on how to do this)
A 1-hour pre-meeting induction (briefing) on Wednesday 20 May at 4.30pm
Reading background papers in the week before the committee meeting
Attending the committee meeting (approx. 3 hours) on Tuesday 14 July 2026
Key Date: Tuesday 14 July 2026 (committee meeting date)
Location: Both meetings will take place virtually, via Zoom.
Payment: The committee meeting payment will be £75 for up to and including 4 hours. The pre-briefing meeting payment will be £75.
How to Express an Interest: Please email Charlotte Stephens and Jessica Bailey (Public Involvement Advisor) to express your interest or to ask any questions
(Please quote : NICE ID "ID6516" in the title of your email. You will be asked to complete a nomination form outlining your experience by Wednesday 22 April – we will provide you with guidance on how to do this)
How Members Will Be Selected: The Chair of the committee will review all nomination forms and then select the most appropriate patient expert for the topic.
Closing date: 09.00, Monday 20 April 2026